Last reviewed: July 27, 2026
If you are searching for fisetin clinical trial dosage, the short answer is that human studies have used very different fisetin doses and schedules, not one standard regimen. Verified human protocols retrieved from primary sources span 100 mg daily, 500 mg daily for one week per month, 2 mg/kg/day intermittent dosing, 20 mg/kg/day pulse dosing, and a single-dose pharmacokinetic study using a 1000 mg formulation comparison in healthy volunteers. That variation is exactly why readers should be cautious with claims about "the" fisetin human trial dose. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT06431932 PubMed PMID 39269340 PMC / J Nutr Sci 2022
For a broader overview of how these regimens fit into the larger literature, see the main fisetin dosage research summary.
This article includes only doses that could be verified from primary sources retrieved during review, mainly ClinicalTrials.gov and peer-reviewed publications.
Study-by-study fisetin dose comparison table
| Study | Participant population | Dose | Fixed or weight-based | Number of days | Frequency | Total study duration | Safety findings | Efficacy findings | Publication status |
|---|---|---|---|---|---|---|---|---|---|
| NCT07195318 | Relatively healthy middle-aged and older adults | 100 mg | Fixed | 49 dosing days | Daily | 7 weeks | No results posted yet | No efficacy results posted yet | Registered ongoing trial; no peer-reviewed outcome paper identified |
| PMID 39269340 | Healthy adults over age 50 | 500 mg | Fixed | 7 days per month | Daily for one week each month | 6 months | No adverse effects noted in 10 participants | Mixed biological-age results; authors said use as an anti-aging agent is not recommended until more extensive studies are done | Peer-reviewed published |
| NCT06133634 | Adults 65+ studying vascular function | 2 mg/kg/day | Weight-based | 6 dosing days total | Two 3-day dosing periods separated by 2 weeks | About 1 month to primary endpoint | No results posted yet | No efficacy results posted yet | Registered ongoing / active trial |
| NCT06431932 | Healthy volunteers and older patients with multimorbidity | 20 mg/kg/day | Weight-based | 2 consecutive days | Single short pulse protocol in visible sub-study description | Follow-up up to about 3 months | No results posted yet | No efficacy results posted yet | Registered ongoing trial |
| NCT03430037 | Postmenopausal women age 70+ | 20 mg/kg/day | Weight-based | 2 consecutive days each month | Repeated monthly pulse for 2 consecutive months | About 2 months of dosing | No published safety results identified | No published efficacy results identified | Registered trial; no peer-reviewed outcome paper identified |
| NCT03675724 | Older adults age 70+ | 20 mg/kg/day | Weight-based | 2 consecutive days | One short 2-day course | 7-day primary outcome window | No published safety findings identified | No published efficacy findings identified | Terminated; no peer-reviewed outcome paper identified |
| NCT04771611 | At-risk adult COVID-19 outpatients | ~20 mg/kg/day | Weight-based | 4 dosing days total | Days 0, 1, 8, and 9 | 60-day primary outcome window | Registry tracked serious adverse events; peer-reviewed safety interpretation not identified | Registry results posted; no peer-reviewed efficacy paper identified | Completed with registry results posted |
| NCT04770064 | Adults with mild to moderate knee osteoarthritis | ~20 mg/kg short-duration arm and 100 mg daily sustained-duration arm | Both | 4 dosing days total in pulse arm; 90 days in daily arm | Pulse arm: 2 days, 28 days off, then 2 more days; Daily arm: every day | 3 months treatment with longer follow-up | No results posted in retrieved sources | No efficacy results posted in retrieved sources | Registered comparative trial; no peer-reviewed outcome paper identified |
| NCT02909686 + PMID 33802381 | Male veterans with Gulf War Illness | Public registry search snippet described fisetin 200–800 mg/day capsules; published paper reports lower- and higher-dose fisetin periods | Fixed | 1 month lower-dose and 1 month higher-dose period | Daily within each treatment month | Multi-month crossover screening protocol | Larger trials still needed to determine safety and optimal dosage | Fisetin did not reduce symptom severity more than placebo | Peer-reviewed published |
| PMC9574875 / PMID 36304817 | 15 healthy volunteers in PK crossover study | Single 1000 mg unformulated fisetin or 1000 mg FF-20 delivering 192 mg fisetin | Fixed | 1 dosing day per period | Single-dose crossover with 10-day washout | Short PK study | Retrieved summary focused on PK and bioavailability rather than clinical safety outcomes | No clinical efficacy endpoint; formulated product showed improved bioavailability | Peer-reviewed published |
Why clinical studies use different fisetin doses
One reason readers get confused about fisetin dosage in clinical trials is that the studies are not all asking the same question. Some are trying to understand pharmacokinetics and bioavailability, some are exploring anti-inflammatory or aging-related biomarkers, some are testing physical function, and some are using fisetin as part of a broader senescence-related hypothesis. A trial testing endothelial function in older adults will not necessarily choose the same dose or schedule as a trial studying osteoarthritis symptoms or a PK crossover in healthy volunteers. ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT04770064 PMC / J Nutr Sci 2022
That is why the human literature includes both low fixed daily dosing and higher short pulse dosing. It is not evidence of a settled protocol. It is evidence that the field is still experimental.
Fixed doses versus weight-based doses
A major divide in the human literature is between fixed-dose studies and weight-based studies.
A fixed dose gives every participant the same nominal milligram amount. Examples include 100 mg daily for 7 weeks in the healthy-aging trial and 500 mg daily for one week per month for six months in the 2024 pilot study. Fixed-dose studies are easier to compare with supplement-label language, but they are not automatically more validated. ClinicalTrials.gov: NCT07195318 PubMed PMID 39269340
A weight-based dose uses milligrams per kilogram. Examples include 2 mg/kg/day in the vascular-function study and 20 mg/kg/day in several senescence-oriented protocols. Weight-based dosing means the total amount changes with body weight, which is one reason fisetin 20 mg kg trial searches are so common. ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT06431932 ClinicalTrials.gov: NCT03430037
The important point is that 100 mg, 500 mg, and 20 mg/kg/day are not directly comparable unless you also compare body weight, timing, duration, and study purpose.
Daily versus intermittent administration
The next big difference is schedule.
Some human studies use daily administration. The clearest examples are 100 mg daily for 7 weeks and 100 mg daily for 90 days. Those are sustained low-dose designs. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT04770064
Other studies use intermittent or pulse dosing. The vascular trial uses 2 mg/kg/day in two 3-day blocks separated by two weeks. The multimorbidity pilot uses 20 mg/kg/day for two consecutive days. The COVID outpatient study used ~20 mg/kg/day on days 0, 1, 8, and 9. ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT06431932 ClinicalTrials.gov: NCT04771611
Still other studies sit in between. The 2024 biological-aging pilot used 500 mg daily for one week per month for six months, which is neither continuous daily use nor a one-time bolus. PubMed PMID 39269340
So when readers ask for a single fisetin study dose, they are often missing the more important variable: the schedule.
Single-dose pharmacokinetic research
Single-dose PK research deserves its own section because it is not testing fisetin the same way outcome trials do.
The best example is the 2022 randomized double-blinded crossover PK study in 15 healthy volunteers. Participants received either 1000 mg unformulated fisetin or 1000 mg of FF-20, a formulation that delivered 192 mg fisetin, with a 10-day washout period between treatments. The study was about bioavailability and pharmacokinetics, not symptom improvement or long-term clinical outcomes. PMC / J Nutr Sci 2022
This matters because people sometimes see "1000 mg" and assume it belongs in the same conversation as clinical-treatment dosing. It does not, at least not directly. A PK study is designed to measure absorption and exposure, not to establish a public-use regimen or clinical efficacy.
Studies examining biological-aging measures
The most visible published human study in this category is the 2024 pilot paper in healthy adults over age 50. It used 500 mg daily for one week per month for six months. According to the abstract, four of ten participants showed a reduction in biological-age measures, five showed an increase, and one showed no change. No adverse effects were noted, but the authors concluded that taking fisetin as an anti-aging agent was not recommended until more extensive studies are done. PubMed PMID 39269340
A separate registered healthy-aging trial is evaluating 100 mg daily for 7 weeks in relatively healthy middle-aged and older adults, but outcome data were not posted in the retrieved source at review time. ClinicalTrials.gov: NCT07195318
Together, these studies show why it is too early to talk about an established "daily anti-aging dose." Human studies exist, but they do not yet support a universal conclusion.
Senolytic trial protocols
Many fisetin discussions online focus on so-called senolytic schedules. In the human registry, these often look like 20 mg/kg/day for short bursts.
Examples include NCT06431932 with 20 mg/kg/day for two consecutive days, NCT03430037 with 20 mg/kg/day for two consecutive days for two consecutive months, and NCT04771611 with ~20 mg/kg/day on days 0, 1, 8, and 9. ClinicalTrials.gov: NCT06431932 ClinicalTrials.gov: NCT03430037 ClinicalTrials.gov: NCT04771611
The osteoarthritis comparison trial is particularly interesting because it puts a weight-based pulse schedule next to a 100 mg daily sustained schedule in the same study framework. That is a useful reminder that researchers are still exploring which kind of exposure pattern is most informative. ClinicalTrials.gov: NCT04770064
But none of these experimental schedules should be mistaken for a consumer recommendation or an approved protocol.
Why clinical-trial dosage is not a consumer recommendation
A clinical-trial dose is not just a number. It comes bundled with eligibility criteria, exclusion criteria, monitoring, follow-up, study products, endpoint definitions, and safety procedures. That is true in the frailty studies, the vascular trial, the COVID trial, and the osteoarthritis programs. ClinicalTrials.gov: NCT03430037 ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT04771611
There is also no consistent human efficacy story yet. The Gulf War Illness crossover study found that fisetin did not reduce symptom severity more than placebo. The small biological-aging pilot found mixed results and explicitly cautioned against recommending fisetin as an anti-aging agent until more extensive studies exist. That is exactly why a fisetin clinical trial dosage should not be converted into self-treatment advice. PubMed PMID 33802381 PubMed PMID 39269340
Evidence gaps
The biggest gap is that the human literature is still small and heterogeneous. Different studies use different populations, endpoints, schedules, and formulations. That makes it hard to compare fisetin human trial dose records head to head. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06133634
Another gap is publication completeness. Some trials are still ongoing. Some have registry results but no peer-reviewed paper identified. Some published studies are small pilots rather than definitive randomized trials. ClinicalTrials.gov: NCT04771611 ClinicalTrials.gov: NCT06431932
A third gap is formulation. The PK study shows that formulation can materially change bioavailability, which means one fisetin product may not behave like another even at the same nominal milligram amount. PMC / J Nutr Sci 2022
FAQ
What is the most common fisetin clinical trial dosage?
There is no single most common validated dose. Human studies have used fixed doses like 100 mg and 500 mg, and weight-based regimens like 2 mg/kg/day and 20 mg/kg/day.
What fisetin human trial dose has been used for healthy aging?
Verified examples include 100 mg daily for 7 weeks in a registered healthy-aging trial and 500 mg daily for one week per month for six months in a published pilot study. ClinicalTrials.gov: NCT07195318 PubMed PMID 39269340
What is the fisetin 20 mg kg trial schedule?
It depends on the study. Verified examples include 2 consecutive days, 2 consecutive days repeated monthly, and 4 dosing days split across days 0, 1, 8, and 9. ClinicalTrials.gov: NCT06431932 ClinicalTrials.gov: NCT03430037 ClinicalTrials.gov: NCT04771611
Has 500 mg fisetin daily been studied?
Yes, but in a specific repeating schedule: 500 mg daily for one week per month for six months in a small pilot study, not as a universal daily recommendation. PubMed PMID 39269340
Are fixed doses and weight-based doses directly comparable?
No. Weight-based doses change with body weight, and schedule differences can also change the meaning of the regimen.
What is the lowest verified human trial dose in the sources reviewed?
Among the clearly verified regimens reviewed here, 100 mg daily is one of the lowest fixed daily amounts, while 2 mg/kg/day is the lowest clearly retrieved weight-based schedule. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06133634
What study used a single-dose fisetin exposure?
The PK crossover study in healthy volunteers used single 1000 mg unformulated fisetin or 1000 mg FF-20 delivering 192 mg fisetin, with a 10-day washout between periods. PMC / J Nutr Sci 2022
Do clinical trials prove these fisetin doses are effective?
No. A study dose is evidence that the amount was tested, not proof that it worked.
Why aren't all registered fisetin studies in this table?
Because this article only includes studies where the dose and schedule could be directly verified from retrieved primary sources during review.
Bottom line
The verified human literature shows that fisetin dosage in clinical trials is highly variable. Human studies and registered trials have used 100 mg daily, 500 mg daily for one week per month, 2 mg/kg/day intermittent regimens, 20 mg/kg/day pulse regimens, and single-dose PK formulations. That tells you two things at once: fisetin has clearly been studied in humans, but there is no single established human trial dose that can be treated as a standard. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT06431932 PubMed PMID 39269340 PMC / J Nutr Sci 2022
This article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making significant changes to your diet, exercise routine, or supplement regimen, especially if you have an existing medical condition, are pregnant or breastfeeding, or take prescription medications.